The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Tough competition in this space. Will be a difficult area to break into and the ceivdr ruling will slow uptake somewhat in eu and fda wont be easy to get for us market. UK market dominated by one player currently and their.multiplex has 6 rather than 4 targets and doesn't require any dna extraction. Total market for this assay in UK fully penetrated is c12-15m gbp. Around half of this is currently using traditional culture methods that will need to be persuaded to.move to a molecular assay.
How so? Enlighten us?
For comparison Smarteye we're reducing headcount as part of cost management around the time of fund raise. They also report quarter results in Aug it will be interesting if others here have information on smarteye hiring increases or if headcount reduction was temporary until rights issue funds hit their accounts. Who knows who will get lions share of DMS business but we have a more than decent shot. CIpia I would say has least scale but could be an additive to say Tesla or Mobileey if they think they can get better value and leverage than getting Smarteye or Seeingmachines. Chicken feed numbers of shares bought and sold and less than many of the posters here total holding and this low grind on tiny volumes frustrates me more than the price. Hopefully a couple of decent announcements and great kpis in the next 2 quarters will bring volume back to rapidly drive price up. Buying here is a steal.
Smarteye report 30/8 so will be interesting to compare and contrast numbers or inferred numbers (Smarteye don't disclose quarterly or running totals in recent history) quarterly revenues and we can judge tone of any outlook or commentary.
Volume so far c0.03% of issued shares. Less than 0.1% of those shares not in the share table of holders on sm website. Noise really and not sure it really warrants the daily grind but market makers doing market making spose. Wish I had a few hundred million as I would take this private in a heartbeat.
This is tedious. Slow grind down on relatively low volume vs shares issued. The days of 10p seem ages away and business today in much better shape IMHO. August numbers likely ignored or worse still used to grind price lower. Very frustrating. I 'spose if long term investing was easy we would all be millionaires.
Re salt in walkers crisps. Probably not secret source they likely literally just reduced amount of salt that coats the crisps by 50%. It's likely being doing that over a period of years and so the comparison maybe to a quite historical date. If you had a bag from say 2010 and today you likely would tell difference but a bag 2023 to. 2022 not so much. If microsalt were used it could reduce by half again due to.the way they create the salt crystal and carrier particle size. In theory walker's could then say they ha e reduce e by 75% which would be better still. That my take and would need some input for sure from maybe a food scientist to back this or refute it.
FFS. CIPIA design win for European oem. Located in 'A' pillar. Based on omnivisin chip. Did I read market cap of Cipia is 8 million GBP correct from Israeli shekels of 38million? No value as far as I could see for contract but for 2024 apparently. Shares up 10ish %. Tick Tock Magna/Valeo/ See, would be nice to see a design win for us too.
Had 2000 shares at 8am bought at around 45p average. By 845 had increased to 15000 at c13p average now. Can sell on H and L all for 6.8p so price creeping back up. Not sure if I will get 13p by close of play and a bit risky but the valuation at 5.8p this am was ridiculous vs IP assets. Dare I say it I could walk away with a small profit by 3pm.
Anyone ha e anything to share on the diagnostics business and recent acquisitions of launch and coris? Any guidance on where they feel they can get to as a business division revenue wise? Any scope for further additions?
Talking up the opportunity for investors has to be managed sensibly. A rampy CEO or those that are super bullish with major grand scheme plans that don't really have and substance end up.inflating the price.way over the actual reality. Four aim examples Versarian, Angle, Novacyt and hvivo. Versarian still burning cash and prob still 10 year too early for graphene. Angle fantastic tech, fda accreditation but still needs.lots of data for ever use case that will drive revenue but heavily reliant in large dx company acquiring as part of a wider portfolio to cut cost of sales. Still 5 year minimum from decent revs and scale unclear( I speak with some expertise in area ) novacyt one trick pony. Maximised the news flow and covid opportunity but massive hangover now covid over and tech supplanted by cephied,roche platform tech. No other replacement ceivd or fda cleared assay.= balloon popped and burning stacks of cash with no clear route to decent clinical.sales (again I speak with commercial expertise in this area) hvivo really ramped by ceo and many promises made. Better business now than 3 years ago but price deflated bur new ceo more measured and can see a decent future in a steady way.
Ramping see by ceo.might give us all some exit options but I feel pmg has given us a fair indication of where we head the size of what is likely to happen over next 5 years and has indicated the car industry won't give all the business to one player. PI's are fickle beasts and castigate a ramp ceo that doesn't deliver. The.market is awful at.moment and rampy.mcrampface at smarteye hasn't done any better for their shareprice either.
Was on linked in. Couldn't link on phone. Tried to refind and seems removed. Was a post saying first full transaction on lloyds but had thought they were already live post trial. Hopefully next trading update will shed more light.
I think I recall there was a share of a magna mirror patent that has this listed as a function or use case using camera and skin tone changes under ir and pupil changes to measure heart rate and blood pressure. Nice to have but likely not so accurate vs say sensor in a garmin/apple watch which themselves less accurate than say a masimo clinical solution you see in hospitals/gp for non invasive/non ecg heart monitoring. False neg/pos could be issue if a signal is hit and then tries to park you in hard shoulder automatically!
I read the white paper and I got the impression the synthetic data and the service the devant offer was more for testing and assessment of performance than out right training for models. Real deal data would always synthetic data as you are measuring not modelling. Modelling and relying on that and I suppose relying on ai in general is prone to data flaws. Real data takes ages and we have that in spades , using the devant stuff I guess shortens data quality testing. There is no short cut to Real data capture .
Thanks Phil. Yep rns may 2022. That was the one I was thinking of and your right that is optics. Prob a special lens with maybe complex elements to allow wide angle and close acuity for the mirror position is my guess and critical to making mirror work I guess.
I did wonder that Lewbo but for life of me I couldn't remember if I dreamt that. Can you recall what rns/date it was announced. In my mind I have this down as a minor footnote on an rns for something else. Anyone know or can point to the rns to that has this information?
RE: Devant. This looks very similar company in a few ways to the two acquired by Smarteye. Affectivia and imotions if I recall. They paid money for them, I guess we maybe licensing initially? This maybe better use of capital resourse, acquisition could be sought later of collaboration becomes material to.our offer. It did lead me to thinking maybe we have a gap in this area that puts us behind smarteye for oms bids as the two smarteye acquisitions were 2 years ago and at the time I thought.maybe was to support their research arm. Would be good to hear more on what this collaboration is expected to deliver and if it is reactive or proactive for bids on table, close to award or those awarded but not announced. Intrigued
Darktrace, pensionbee, kooth, wandisco, kape, zoo digital are some that presented last year. We were there last year also. This sideways grind is soul destroying. Same for smarteye, they back close to 40 sek from 50odd sek post financing. Everything risk off. Both ourselves and smarteye key movers in dms and likely to carve out 40% each and they are declining or flat on the year. Very frustrating. We are priced below magna and Collins licenses. Painful watching this at moment
First customer live on satago via Lloyd's
Have seen other write ups ? Diff trim grades that suggest dms via camera. Again the opaque publicity around suppliers in auto is not helpful and the dual sourcing means difficult to know unless the oem or dms supplier confirms explicitly. I guess we have to watch the numbers of fitments go up and believe. We are supposed to be in some. Eqs models but it was originally pitched that was smarteye.